yes but isnt the relatively high adverse events a worry
"Safety was assessed from all patients enrolled in the study. Intraocular pressure (IOP) increases to 30
millimeters of mercury (mmHg) or greater at any time point, a key adverse event studied in the trial,
were seen in 21.6% of the high dose patients and 16.3% of the low dose patients"
- Forums
- ASX - By Stock
- PVA
- this is going to be massive
this is going to be massive, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PVA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online